Table 1.

Seroprevalence of anti-S and anti-N antibodies, stratified by gender, age group, previous SARS-CoV-2 infection, and vaccination.

	Participants	Anti-S Positive			Anti-N Positive
	n	n (%)	Crude OR (95% CI)	Adjusted OR (95% CI)	n (%)	Crude OR (95% CI)	Adjusted OR (95% CI)
Male	672	574 (85.4)	ref	ref	307 (45.7)	ref	Ref
Female	2227	1865 (83.7)	0.88 (0.69–1.12)	1.02 (0.75–1.39)	1102 (49.5)	1.16 (0.98–1.38)	1.10 (0.90–1.35)
0–17	299	233 (77.9)	ref	ref	183 (61.2)	ref	Ref
18–29	748	609 (81.4)	1.24 (0.89–1.73)	0.48 (0.32–0.71)	403 (53.9)	0.74 (0.56–0.97)	0.60 (0.44–0.82)
30–39	757	617 (81.5)	1.25 (0.90–1.74)	0.40 (0.27–0.60)	385 (50.9)	0.66 (0.50–0.86)	0.52 (0.38–0.71)
40–49	306	264 (86.3)	1.78 (1.16–2.72)	0.35 (0.21–0.58)	141 (46.1)	0.54 (0.39–0.75)	0.48 (0.33–0.70)
50–59	327	294 (89.9)	2.52 (1.61–3.97)	0.46 (0.27–0.78)	147 (45.0)	0.52 (0.38–0.71)	0.60 (0.41–0.86)
60–69	251	228 (90.8)	2.81 (1.69–4.67)	0.47 (0.26–0.85)	91 (36.3)	0.36 (0.25–0.51)	0.53 (0.36–0.79)
70+	211	194 (91.9)	3.23 (1.84–5.69)	0.33 (0.16–0.67)	59 (28.0)	0.25 (0.17–0.36)	0.48 (0.31–0.74)
Never infected	1291	1031 (79.9)	ref	ref	365 (28.3)	ref	ref
Infected ≥ 1	1608	1408 (87.6)	1.78 (1.45–2.17)	3.71 (2.92–4.72)	1044 (64.9)	4.70 (4.01–5.50)	4.45 (3.75–5.28)
Never vaccinated	1324	906 (68.4)	ref	ref	775 (58.5)	ref	ref
Partially vaccinated	71	70 (98.6)	32.30 (4.47–233.28)	28.27 (3.89–205.57)	34 (47.9)	0.65 (0.40–1.05)	0.48 (0.29–0.78)
Completely vaccinated	858	824 (96.0)	11.18 (7.79–16.06)	15.91 (10.88–23.26)	410 (47.8)	0.65 (0.55–0.77)	0.73 (0.61–0.89)
Additional dose	646	639 (98.9)	42.12 (19.82–89.50)	91.69 (41.40–203.08)	190 (29.4)	0.30 (0.24–0.36)	0.53 (0.41–0.67)